glp 1 mimetic GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Clinical Focus on GLP-1 Agonists

The Upside: GLP-1 Wont Stop You From Building Muscle The big point here is GLP-1 medications dont get in the way of how your body builds muscle

Data from the FIGHT and LIVE trials, inclusive of patients with median left ventricular ejection fraction of 25% and 45%, respectively, associated GLP-1 receptor agonists use with neutral or even harmful effects in patients with heart failure with reduced ejection fraction (HFrEF): liraglutide 1.8 mg/daily administration did not improve mortality and rehospitalisation in patients with advanced heart failure, left ventricular function, or exercise capacity stable among chronic heart failure patients, and suggested an increase in cardiac events [122, 123]

10.1196/annals.1320.003

Liu Q, Li S, Quan H, Li J

J Cyst Fibros 2(4):195198